Cargando…

Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review

BACKGROUND: Rare cancers, as defined by the European Union, occur in fewer than 15 out of 100,000 people each year. The International Rare Cancer Consortium defines rare cancer incidence as less than six per 100,000 per year. There is a growing number of reports of the efficacy of immune checkpoint...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petrelli, Fausto, Consoli, Francesca, Ghidini, Antonio, Perego, Gianluca, Luciani, Andrea, Mercurio, Paola, Berruti, Alfredo, Grisanti, Salvatore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488393/ https://www.ncbi.nlm.nih.gov/pubmed/34616395 http://dx.doi.org/10.3389/fimmu.2021.720748

Ejemplares similares

Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy
por: Consoli, Francesca, et al.
Publicado: (2019)

Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
por: Petrelli, Fausto, et al.
Publicado: (2021)

Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies
por: Petrelli, Fausto, et al.
Publicado: (2021)

Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies
por: Amoroso, V., et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis
por: Gemelli, Maria, et al.
Publicado: (2022)

Topotecan or other agents as second-line therapy for relapsed small-cell lung cancer: A meta-analysis of randomized studies
por: Petrelli, Fausto, et al.
Publicado: (2021)

Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis
por: Petrelli, Fausto, et al.
Publicado: (2021)

Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis
por: Tomasello, Gianluca, et al.
Publicado: (2022)

Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Petrelli, Fausto, et al.
Publicado: (2020)

The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies
por: González-Navajas, Jose M., et al.
Publicado: (2021)

Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
por: Wong, Selina K., et al.
Publicado: (2021)

Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review
por: Li, Honglin, et al.
Publicado: (2023)

Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen
por: Turla, Antonella, et al.
Publicado: (2022)

The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures
por: Dalla Volta, Alberto, et al.
Publicado: (2020)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
por: Consoli, Francesca, et al.
Publicado: (2020)

Editorial: Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex Factors
por: Chong, Pei Pei, et al.
Publicado: (2022)

Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors
por: Giordan, Quentin, et al.
Publicado: (2021)

Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade
por: Appleton, Elizabeth, et al.
Publicado: (2021)

Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis
por: Petrelli, Fausto, et al.
Publicado: (2020)

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
por: Botticelli, Andrea, et al.
Publicado: (2017)

Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies
por: Petrelli, Fausto, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy
por: Silva, Saulo Brito, et al.
Publicado: (2022)

Analysis of Tumor Glycosylation Characteristics and Implications for Immune Checkpoint Inhibitor’s Efficacy for Breast Cancer
por: Lv, Wenchang, et al.
Publicado: (2022)

Biomarkers of related driver genes predict anti-tumor efficacy of immune checkpoint inhibitors
por: Jiang, Shuai, et al.
Publicado: (2022)

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor
por: Hamada, Kazuyuki, et al.
Publicado: (2023)

Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma
por: Wang, Qi, et al.
Publicado: (2023)

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2023)

The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis
por: Petrelli, Fausto, et al.
Publicado: (2023)

Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options
por: Grizzi, Giulia, et al.
Publicado: (2020)

Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials
por: Bersanelli, Melissa, et al.
Publicado: (2021)

Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response
por: Yang, Fei, et al.
Publicado: (2022)

Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer
por: Lin, Anqi, et al.
Publicado: (2021)

Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study
por: Liu, Rong, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis
por: Noori, Maryam, et al.
Publicado: (2023)

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
por: Petrelli, Fausto, et al.
Publicado: (2016)

Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines?
por: Grisanti, Salvatore, et al.
Publicado: (2021)

Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study
por: Wei, Fuqun, et al.
Publicado: (2022)

Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
por: Westdorp, Harm, et al.
Publicado: (2021)

Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases
por: von Knethen, Andreas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_14knu63bp17du99qpuqthv392e